Hearing loss and dementia

Iliffe and Manthorpe’s editorial in the August issue1 is apposite in view of the publication in July of the Lancet Commissions’ report Dementia prevention, intervention, and care, which expands on several of the themes raised.2 In particular, the editorial’s focus on the role of general practice in prevention and research is to be welcomed. However they do not mention hearing loss, to which the Lancet report devotes considerable space and ascribes a significant potential preventive role. Hearing loss is independently associated with developing dementia in about one-third of cases. Recent research has suggested that use of hearing aids may reduce or prevent the increased prevalence of dementia seen in adults with hearing loss.3,4 This needs confirmation, as current evidence is weak due to the large number of confounding factors. General practice is ideally suited to carry out this research thanks to our large-scale and long-duration databases. In the meanwhile, GPs are likely to see increasing numbers of patients asking for referral for hearing aids, as some in the commercial sector are stating this benefit of hearing aids as fact. Such referral should be expedited; GPs are sometimes accused of minimising hearing loss and delaying referral, but early users of hearing aids are more likely to use aids successfully over a longer timescale than is thought. As these young patients turn 6 and 12 to avoid the potential for undertreatment, GPs need to happen now.

Adrenaline auto-injector prescribing may be putting patients at risk

Adrenaline auto-injector (AAI) prescribing for children in UK primary care has increased dramatically since 2000.5 As these young patients grow older, an increasing number of adults will require AAIs to mitigate their risk of an anaphylactic reaction. Current National Institute for Health and Care Excellence (NICE) guidance advises that adults and children aged >12 years should receive 500 μg adrenaline intramuscularly at the onset of suspected anaphylaxis, with doses of 300 μg and 150 μg advised for children aged 6–12 years and <6 years respectively.6

A recent audit of AAI prescribing Undertook while working at a West London surgery found 100% adherence to these doses for patients aged <6 years, but adherence fell to 62% in children aged 6–12 years and to just 3% in patients aged >12 years. The current lack of a 500 μg AAI in the popular EpiPen range may be a factor in the undertosing of adults at risk of anaphylaxis (96% of AAIs prescribed were from this range). Five-hundred microgram AAIs are available as part of the local formulary at a similar price to ‘EpiPen’ products but appear to be seldom prescribed despite this. Care should also be taken to ensure that the dose of AAI prescribed is increased appropriately as young patients turn 6 and 12 to avoid the potential for undertreatment of life-threatening anaphylactic reactions.

Bad Medicine: The medical untouchables

As a named petitioner in the Scottish Parliament public petition cited by Des Spence in this article,1 I would like to thank Dr Spence wholeheartedly for his support on TV and radio, and now in this journal. I would also like to thank the BJGP for publication. We too have been ‘banging on about this’, [the harm caused by prescription drugs] on behalf of patients, for years. We have become acutely aware of how ‘untouchable’ the topic is for doctors, and aware of their extreme discomfort when patients try to flag up the issues. GPs, especially, seem to have been placed in an extraordinarily difficult situation altogether by a system that has failed to provide them with the guidance and support that they surely deserve. Perhaps, between us all, we can truly recognise what has gone wrong and start to really communicate collaboratively about what needs to happen now.

REFERENCES

1. Iliffe S, Manthorpe J. Dementia: is the biopsychosocial model vindicated? Br J Gen Pract 2017; DOI: https://doi.org/10.3399/bjgp17X691781.
7. DOI: https://doi.org/10.3399/bjgp17X692669

Adrenaline auto-injector prescribing may be putting patients at risk

Adrenaline auto-injector (AAI) prescribing for children in UK primary care has increased dramatically since 2000.5 As these young patients grow older, an increasing number of adults will require AAIs to mitigate their risk of an anaphylactic reaction. Current National Institute for Health and Care Excellence (NICE) guidance advises that adults and children aged >12 years should receive 500 μg adrenaline intramuscularly at the onset of suspected anaphylaxis, with doses of 300 μg and 150 μg advised for children aged 6–12 years and <6 years respectively.6

A recent audit of AAI prescribing Undertook while working at a West London surgery found 100% adherence to these doses for patients aged <6 years, but adherence fell to 62% in children aged 6–12 years and to just 3% in patients aged >12 years. The current lack of a 500 μg AAI in the popular EpiPen range may be a factor in the undertosing of adults at risk of anaphylaxis (96% of AAIs prescribed were from this range). Five-hundred microgram AAIs are available as part of the local formulary at a similar price to ‘EpiPen’ products but appear to be seldom prescribed despite this. Care should also be taken to ensure that the dose of AAI prescribed is increased appropriately as young patients turn 6 and 12 to avoid the potential for undertreatment of life-threatening anaphylactic reactions.

Duncan Baily, Foundation Year 2 Doctor, North West Thames Foundation School. E-mail: duncan.baily@doctors.org.uk

REFERENCES


Letters

All letters are subject to editing and may be shortened. General letters can be sent to bjpdisconrcgp.org.uk (please include your postal address for publication), and letters responding directly to BJGP articles can be submitted online via eLetters. We regret we cannot notify authors regarding publication. For submission instructions visit: bjp.org/letters